Enorama Pharma AB (ERMA) - Total Liabilities
Based on the latest financial reports, Enorama Pharma AB (ERMA) has total liabilities worth Skr59.58 Million SEK (≈ $6.41 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Enorama Pharma AB (ERMA) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Enorama Pharma AB - Total Liabilities Trend (2014–2025)
This chart illustrates how Enorama Pharma AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ERMA total asset value.
Enorama Pharma AB Competitors by Total Liabilities
The table below lists competitors of Enorama Pharma AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SKK Holdings Limited
NASDAQ:SKK
|
USA | $24.40 Million |
|
Wide Open Agriculture Ltd
AU:WOA
|
Australia | AU$1.60 Million |
|
Me Group International PLC
LSE:MEGP
|
UK | GBX127.43 Million |
|
Optima Prima Metal Sinergi
JK:OPMS
|
Indonesia | Rp1.30 Billion |
|
Gasporox AB (publ)
ST:GPX
|
Sweden | Skr29.19 Million |
|
Activex Ltd
AU:AIV
|
Australia | AU$2.21 Million |
|
APOLLO GROUP-A
F:APO
|
Germany | €1.28 Million |
|
Pentanet Ltd
AU:5GG
|
Australia | AU$12.06 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Enorama Pharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ERMA net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.63 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enorama Pharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enorama Pharma AB (2014–2025)
The table below shows the annual total liabilities of Enorama Pharma AB from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr31.71 Million ≈ $3.41 Million |
+291.95% |
| 2024-12-31 | Skr8.09 Million ≈ $870.72K |
-45.50% |
| 2023-12-31 | Skr14.85 Million ≈ $1.60 Million |
-13.67% |
| 2022-12-31 | Skr17.20 Million ≈ $1.85 Million |
-41.86% |
| 2021-12-31 | Skr29.58 Million ≈ $3.18 Million |
-24.40% |
| 2020-12-31 | Skr39.13 Million ≈ $4.21 Million |
+10.52% |
| 2019-12-31 | Skr35.40 Million ≈ $3.81 Million |
+62.33% |
| 2018-12-31 | Skr21.81 Million ≈ $2.35 Million |
+168.41% |
| 2017-12-31 | Skr8.13 Million ≈ $874.50K |
+78.73% |
| 2016-12-31 | Skr4.55 Million ≈ $489.27K |
+71.95% |
| 2015-12-31 | Skr2.64 Million ≈ $284.54K |
+155.71% |
| 2014-12-31 | Skr1.03 Million ≈ $111.27K |
-- |
About Enorama Pharma AB
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells tobacco-free white snus in Sweden. It offers its products under the NIC-S brand name. The company was incorporated in 2006 and is based in Stockholm, Sweden.